Taxas de continuidade do tratamento da hepatite C em pacientes ingênuos de genótipo 1 no sistema público de saúde brasileiro
Tipo de documento
Apresentação
Descrição
Resumo apresentado na The Professional Society for Health Economics and Outcomes Research (ISPOR)
Fonte
ISPOR
Ano de publicação
2011
Referência (Vancouver)
Mussolino F, Vaz P, Morais AD, Pereira ML. Hepatitis c treatment continuation rates in treatment-naïve genotype 1 patients in the Brazilian public health care system [Internet]. In: ISPOR Europe 2011; Madrid, Spain. Disponível em: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-14th-annual-european-congress/hepatitis-c-treatment-continuation-rates-in-treatment-naive-genotype-1-patients-in-the-brazilian-public-health-care-system
Hepatitis C Treatment Continuation Rates in Treatment-naïve Genotype 1 Patients in the Brazilian Public Health Care System.
Document type
Presentation
Description
Abstract presented at The Professional Society for Health Economics and Outcomes Research (ISPOR)
Source
ISPOR
Publication year
2011
Reference (Vancouver)
Mussolino F, Vaz P, Morais AD, Pereira ML. Hepatitis c treatment continuation rates in treatment-naïve genotype 1 patients in the Brazilian public health care system [Internet]. In: ISPOR Europe 2011; Madrid, Spain. Available from: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-14th-annual-european-congress/hepatitis-c-treatment-continuation-rates-in-treatment-naive-genotype-1-patients-in-the-brazilian-public-health-care-system
Objetivos: Determinar as taxas reais de continuidade do tratamento da Hepatite C crônica (HCV) a partir de um banco de dados de dispensa de medicamentos no sistema público de saúde Brasileiro. Métodos: Dados mensais de um banco de dados público de dispensa de medicamentos foram analisados ao longo de um período de 17 meses. A coorte de pacientes foi definida como todos os pacientes novos com HCV (CID10 B18.2) que iniciaram o tratamento entre janeiro e dezembro de 2009. Para identificar pacientes com genótipo 1 (G1) de HCV, assumiu-se que os pacientes com G1 iniciaram o tratamento com as formas peguiladas dos interferons (pegIFN), conforme definido pelas diretrizes nacionais Brasileiras para HCV. Resultados: Entre janeiro e dezembro de 2009, 10.992 pacientes iniciaram tratamento para HCV. Cerca de 58% desses pacientes eram do sexo masculino, com idade média de 49,7 anos. Desses, 82% dos pacientes (9.019) foram considerados G1, pois iniciaram o tratamento com pegIFN e/ou ribavirina. Quase todos os pacientes (97%) iniciaram o tratamento com a combinação pegIFN e ribavirina, com uma divisão igual entre as duas marcas de pegIFN. Para todos os pacientes com HCV, a duração média/mediana do tratamento foi de 38,3/40 semanas em comparação com 40,2/44,0 semanas para pacientes com G1. Na semana 48, 63% de todos os pacientes com HCV haviam descontinuado o tratamento em comparação com 58% dos pacientes com G1. Na semana 24, cerca de 19% de todos os pacientes com HCV haviam descontinuado o tratamento em comparação com 18% dos pacientes com G1. A duração máxima observada do tratamento foi de 85 semanas tanto para pacientes com HCV quanto para pacientes com G1. Conclusões: As taxas de descontinuação antes da semana 24 foram semelhantes entre todos os pacientes com HCV e os pacientes com G1. Embora 48 semanas de tratamento seja a duração estabelecida para pacientes com G1, a maioria dos pacientes descontinua o tratamento mais cedo. No entanto, esses dados não garantem que os pacientes realmente receberam o tratamento, pois se baseiam na dispensa de medicamentos.
Notas
O registro foi originalmente publicado em inglês. A versão em português foi traduzida com o apoio de inteligência artificial.
Abstract
Objetives: Determine real-life treatment continuation rates of chronic Hepatitis C (HCV) treatment from a database of medicine dispensation in the Brazilian public healthcare system. Methods: Monthly data from a public database of medicine dispensation was analyzed for a period of 17 months. The patient cohort was defined as all new HCV (CID10 B18.2) patients initiating treatment between January and December 2009. To identify HCV genotype 1 (G1) patients, it was assumed G1 patients initiated treatment with the pegylated forms of the interferons (pegIFN), as defined by the Brazillian national guidelines for HCV. Results: Between January and December 2009, 10,992 patients began treatment for HCV. Around 58% of these patients were male with a median age of 49.7 years. Of these, 82% of patients (9,019) were considered G1 as they began treatment with pegIFN and/or ribavirin. Almost all patients (97%) began treatment with the treatment combination pegIFN and ribavirin, with an equal split among both brands of pegIFN. For all HCV patients treatment mean/median was 38,3/40 weeks compared to 40.2/44.0 weeks for G1 patients. At week 48, 63% of all HCV patients had discontinued treatment compared to 58% of G1 patients. At week 24, around 19% of all HCV patients had discontinued treatment compared to 18% of G1 patients. The maximum observed treatment duration was 85 weeks in both all HCV and G1 patients. Conclusions: Discontinuation rates before week 24 were similar between all HCV and G1 patients. Although 48 weeks of treatment is the established duration for G1 patients, the majority of patients discontinue treatment earlier. These data, however, do not guarantee patients actually receive treatment, as it follows medicine dispensation.
Notes
The record was originally published in English. The Portuguese version was translated with the aid of artificial intelligence.
